Effexor and Hyperparathyroidism secondary - a phase IV clinical study of FDA data

Summary:

Hyperparathyroidism secondary is reported as a side effect among people who take Effexor (venlafaxine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Nexium, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Hyperparathyroidism secondary when taking Effexor. It is created by eHealthMe based on reports of 92,291 people who have side effects when taking Effexor from the FDA, and is updated regularly.

What is Effexor?

Effexor has active ingredients of venlafaxine hydrochloride. It is often used in depression. eHealthMe is studying from 99,493 Effexor users. Check the latest studies of Effexor.

What is Hyperparathyroidism secondary?

Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary) is found to be associated with 697 drugs and 461 conditions by eHealthMe. Check the latest studies of Hyperparathyroidism secondary.

On Jul, 07, 2026

92,291 people reported to have side effects when taking Effexor.
Among them, 53 people (0.06%) have Hyperparathyroidism secondary.

Could Effexor cause Hyperparathyroidism secondary?

Among these 53 people:

How long have people been on Effexor when they have Hyperparathyroidism secondary? *

What is the gender of people who have Hyperparathyroidism secondary when taking Effexor? *

female: 73.08 %
male: 26.92 %

What is the age of people who have Hyperparathyroidism secondary when taking Effexor? *

What are other drugs people take besides Effexor? *

What are other side effects people have besides Hyperparathyroidism secondary? *

Chronic Kidney Disease: 50 people, 94.34%
Acute Kidney Failure: 35 people, 66.04%
Nephrogenic Anaemia (anaemia due to kidney disease): 32 people, 60.38%
Renal Injury (kidney injury): 14 people, 26.42%
Interstitial Nephritis (inflammation of the kidney): 5 people, 9.43%
Nephropathy (damage to or disease of a kidney): 4 people, 7.55%
Cardiac Failure Congestive: 3 people, 5.66%
Renal Tubular Necrosis (death of kidney tubules): 3 people, 5.66%
Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 2 people, 3.77%
Scrotal Abscess (pus in scrotum): 2 people, 3.77%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 43 people, 81.13%
High Blood Pressure: 22 people, 41.51%
Pain: 20 people, 37.74%
High Blood Cholesterol: 20 people, 37.74%
Infection: 17 people, 32.08%
Fluid Retention (an abnormal accumulation of fluid in the blood): 16 people, 30.19%
Headache (pain in head): 12 people, 22.64%
Urinary Tract Infection: 10 people, 18.87%
Hypersensitivity: 10 people, 18.87%
Indigestion: 8 people, 15.09%

* Approximation only. Some reports may have incomplete information.

Do you take Effexor and have Hyperparathyroidism secondary?

- Check whether Hyperparathyroidism secondary is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Effexor:

Effexor (99,493 reports)

Browse all side effects of Effexor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperparathyroidism secondary:

Hyperparathyroidism secondary (697 drugs)

Browse all the conditions that are associated with Hyperparathyroidism secondary:

Hyperparathyroidism secondary (461 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on venlafaxine hydrochloride (the active ingredients of Effexor) and Effexor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.